Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma
Authors
Keywords
-
Journal
Pigment Cell & Melanoma Research
Volume 31, Issue 1, Pages 110-114
Publisher
Wiley
Online
2017-09-18
DOI
10.1111/pcmr.12644
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795).
- (2017) R. Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies
- (2016) Alain P. Algazi et al. CANCER
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association BetweenNRASandBRAFMutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma
- (2015) Nancy E. Thomas et al. JAMA Oncology
- Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
- (2014) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
- (2014) P. L. Bedard et al. CLINICAL CANCER RESEARCH
- Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of WTBRAF/WTNRAS melanoma cells to vemurafenib
- (2014) Mohammad Krayem et al. EUROPEAN JOURNAL OF CANCER
- Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma
- (2014) Richard D. Carvajal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- (2013) Paolo A Ascierto et al. LANCET ONCOLOGY
- BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
- (2012) Maria Colombino et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
- (2011) Nikhil Wagle et al. Cancer Discovery
- Mutations inGNA11in Uveal Melanoma
- (2010) Catherine D. Van Raamsdonk et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors
- (2009) Bijay S. Jaiswal et al. PLoS One
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search